Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
China · Delayed Price · Currency is CNY 29.24
-0.05 (-0.17%)
At close: Feb 27, 2026
SHE:301089 Revenue
Tuoxin Pharmaceutical Group had revenue of 89.65M CNY in the quarter ending September 30, 2025, a decrease of -16.21%. This brings the company's revenue in the last twelve months to 367.49M, down -11.48% year-over-year. In the year 2024, Tuoxin Pharmaceutical Group had annual revenue of 421.69M, down -49.53%.
Revenue (ttm)
367.49M
Revenue Growth
-11.48%
P/S Ratio
10.07
Revenue / Employee
236.94K
Employees
1,551
Market Cap
3.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 421.69M | -413.82M | -49.53% |
| Dec 31, 2023 | 835.51M | 50.79M | 6.47% |
| Jan 1, 2023 | 784.72M | 282.24M | 56.17% |
| Jan 1, 2022 | 502.48M | -25.46M | -4.82% |
| Dec 31, 2020 | 527.94M | 141.98M | 36.79% |
| Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PKU HealthCare Corp.,Ltd. | 1.76B |
| Nanjing Well Pharmaceutical Group | 1.31B |
| Huaren Pharmaceutical | 1.26B |
| Hunan Hansen Pharmaceutical | 1.05B |
| Anhui Sunhere Pharmaceutical Excipients | 934.72M |
| Harbin Medisan Pharmaceutical | 874.60M |
| Zhejiang Shengda Bio-Pharm | 839.82M |
| Zhejiang Cheng Yi Pharmaceutical | 790.86M |